We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
United Therapeutics Corporation

United Therapeutics Corporation (UTHR)

Closed July 15 4:00PM
( 0.00% )
Pre Market: 4:00AM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
0.00 Day's Range 0.00
208.6249 52 Week Range 330.00
Market Cap
Previous Close
Last Trade
Last Trade Time
Financial Volume
Average Volume (3m)
Shares Outstanding
Dividend Yield
PE Ratio
Earnings Per Share (EPS)
Net Profit

About United Therapeutics Corporation

United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are bas... United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension. Show more

Pharmaceutical Preparations
Pharmaceutical Preparations
Wilmington, Delaware, USA
United Therapeutics Corporation is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker UTHR. The last closing price for United Therapeutics was $327.26. Over the last year, United Therapeutics shares have traded in a share price range of $ 208.6249 to $ 330.00.

United Therapeutics currently has 44,355,694 shares outstanding. The market capitalization of United Therapeutics is $14.52 billion. United Therapeutics has a price to earnings ratio (PE ratio) of 14.74.

United Therapeutics (UTHR) Options Flow Summary

Overall Flow


Net Premium


Calls / Puts


Buys / Sells




Sweeps Ratio


UTHR Latest News

United Therapeutics Corporation Announces Full Enrollment of the TETON 2 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis

Over 100,000 patients in the United States have IPF, with two approved therapies available that only slow the course of disease progression Top line data expected in the second half of 2025...

United Therapeutics Corporation Announces Election of Jan Malcolm to its Board of Directors

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced the addition of former Minnesota Commissioner of Health Jan Malcolm to its Board of Directors. Ms. Malcolm...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP


View all
  • Most Active
  • % Gainers
  • % Losers
CDTConduit Pharmaceuticals Inc
$ 0.4588
WNWMeiwu Technology Company Ltd
$ 1.245
SYRASyra Health Corporation
$ 1.75
WINTWindtree Therapeutics Inc
$ 4.50
TPCSTechPrecision Corporation
$ 4.36
GRNQGreenpro Capital Corporation
$ 0.9665
AMIXAutonomix Medical Inc
$ 1.14
AREBAmerican Rebel Holdings Inc
$ 0.561
$ 7.82
MFImF International Ltd
$ 0.80
CDTConduit Pharmaceuticals Inc
$ 0.4573
KRKR36Kr Holdings Inc
$ 0.3125
SLNASelina Hospitality PLC
$ 0.0662
WNWMeiwu Technology Company Ltd
$ 1.23
MAXNMaxeon Solar Technologies Ltd
$ 0.2211

UTHR Discussion

View Posts
crudeoil24 crudeoil24 3 years ago
UTHR @ 196.30 > United Therapeutics shares are trading higher after the company announced that the FDA approved the launch of its Tyvaso for the treatment of pulmonary hypertension associated with interstitial lung disease.
Cbdpotential Cbdpotential 3 years ago
TFMG TFMG 4 years ago

$UTHR | #UnitedTherapeutics Breakout Setup

Potential entry above $ 144.50
Target price $ 152.00
Indicators in reversal

jgrabar jgrabar 4 years ago
irat1onal irat1onal 5 years ago
ideaXme interview with Commander (ret) Dr. Luis Alvarez, Director of Organ Manufacturing, United Therapeutics where he works on lung bio-engineering -
TREND1 TREND1 6 years ago
TREND1 TREND1 6 years ago
FLOAT = 38 M
TREND1 TREND1 6 years ago
TREND1 TREND1 6 years ago
EPS= $9.50
$Pistol Pete$ $Pistol Pete$ 6 years ago
$UTHR huge news between UTHR and MNKD
ValueInvestor15 ValueInvestor15 8 years ago
Multiple valuation analyses show United Therapeutics is highly undervalued. Earnings tomorrow to be the catalyst?


$Pistol Pete$ $Pistol Pete$ 8 years ago
$UTHR Daily and Weekly Charts

$Pistol Pete$ $Pistol Pete$ 8 years ago
$UTHR Daily Chart

stocktrademan stocktrademan 9 years ago
$UTHR recent news/filings

bullish 158.63
moving average support
higher highs higher lows uptrend

## source:

Tue, 08 Dec 2015 18:16:37 GMT ~ UNITED THERAPEUTICS CORP Financials

read full:

Mon, 07 Dec 2015 12:32:37 GMT ~ SteadyMed Demonstrates Potential for Reduced Infusion Site Sensitivity Associated With Trevyent Compared to Remodulin

[at noodls] - SAN RAMON, Calif., Dec. 7, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value diseases ...

read full:

Mon, 07 Dec 2015 12:00:00 GMT ~ SteadyMed Demonstrates Potential for Reduced Infusion Site Sensitivity Associated With Trevyent Compared to Remodulin

[GlobeNewswire] - SAN RAMON, Calif. -- SteadyMed Ltd. , a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value diseases with unmet parenteral delivery needs, today ...

read full:

Tue, 01 Dec 2015 21:03:31 GMT ~ Top Stock Picks of Multi-Billion Dollar, Healthcare-Focused Fund Palo Alto Investors

read full:

Tue, 01 Dec 2015 15:31:12 GMT ~ Hedge Funds Are Selling YPF SA (ADR) (YPF)

read full:

$UTHR charts

basic chart ## source:

basic chart ## source:

big daily chart ## source:

big weekly chart ## source:

$UTHR company information

## source:

Ticker: $UTHR
OTC Market Place: Not Available
CIK code: 0001082554
Company name: United Therapeutics Corp.
Incorporated In: DE, USA

$UTHR share structure

## source:

Market Value: $6,958,029,036 a/o Dec 14, 2015
Shares Outstanding: 45,629,412 a/o Oct 21, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.01

$UTHR extra dd links

Company name: United Therapeutics Corp.
After Hours Quote (
Option Chain (
Historical Prices (
Company Profile (
Industry (

Market Stream (
Latest news ( -

Analyst Research (
Guru Analysis (
Stock Report (
Competitors (
Stock Consultant (
Stock Comparison (
Investopedia (
Research Reports (
Basic Tech. Analysis (
Barchart (
Spoke company information (
Corporation WIKI (

Call Transcripts (
Annual Report (
Income Statement (
Revenue/EPS (
SEC Filings (
Edgar filings (
Latest filings (
Latest financials (
Short Interest (
Dividend History (
RegSho (
OTC Short Report (
Short Sales (
Key Statistics (
Insider Roster (
Income Statement (
Balance Sheet (
Cash Flow (

Major holdings (
Insider transactions (
Insider transactions (
Insider transactions (
Ownership Summary (
Institutional Holdings (
Insiders (SEC Form 4) (
Insider Disclosure (

Market Watch (
Bloomberg (
Morningstar (
Bussinessweek (

$UTHR DD Notes ~
maytepper maytepper 10 years ago
$UTHR H.C. Wainwright Reiterates Buy On United Therapeutics Following Healthcare Conference
ClayTrader ClayTrader 10 years ago
* * $ECYT Video Chart 8-29-14 * *

Link to Video - click here to watch the technical chart video
ClayTrader ClayTrader 10 years ago
* * $UTHR Video Chart 8-26-14 * *

Link to Video - click here to watch the technical chart video
mlkrborn mlkrborn 12 years ago
New drug application for high blood pressure rejected $43 now.
Roche Hit By European Infringement Charge, XOMA Offers Shares: Healthcare Business Recap
By Mark Lawson | More Articles
October 24, 2012
The European Medicines Agency on Wednesday affirmed that it is bringing an infringement procedure against Roche (RHHBY.OB), claiming that the company did not properly check out some 80,000 reports of issues received from U.S. patients and doctors relating to 19 of the firm’s drugs, including the top performers Herceptin and Avastin. Roche could be penalized by as much as 5 percent of its yearly revenues if found guilty.
Shares of United Therapeutics Corporation (NASDAQ:UTHR) go over the cliff on word that on Wednesday the FDA rejected the firm’s new drug application for treprostinil, which is an oral treatment for high blood pressure. The agency said that it is uncertain as to whether another evaluation would help reverse its decision, but did indicate that if the company elects to conduct a further trial, it should consider a fixed dose design and more frequent dosing.
Catalysts are critical to discovering winning stocks. Check out our newest CHEAT SHEET stock picks now.
The drug maker XOMA (NASDAQ:XOMA) will to offer 13.33 million shares of common stock at $3 per share, and intends to use the proceeds for ongoing development and testing of its diabetes treatments gevokizumab and XMet platform, along with other corporate purposes.
Discovery Laboratories (NASDAQ:DSCO) shares sharply dip but rebound on the news that the commercial intro of its Surfaxin liquid medication to treat Infant Respiratory Distress Syndrome will probably be postponed until the second quarter of next year. The launch had previously been planned to occur by the end of the current year.
Penny Roger$ Penny Roger$ 12 years ago
~ Monday! $UTHR ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $UTHR ~ Earnings expected on Monday *
Want more like this? Search Keyword: MACMONEY >>> <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.

~ Google Finance:
~ Google Fin Options: h
~ Yahoo! Finance ~ Stats:
~ Yahoo! Finance ~ Profile:
~ BusyStock:

<<<<<< >>>>>>

*If the earnings date is in error please ignore error. I do my best.
mlkrborn mlkrborn 13 years ago
UTHR hit almost 52 weeks low level-$40 on failure of oral version:
United Therapeutics down as drug misses study goal
United Therapeutics says oral treprostinil missed goal in late-stage trial, and stock sinks

Related Quotes
Symbol Price Change
UTHR 40.13 -8.62

On Wednesday August 24, 2011, 11:35 am EDT

NEW YORK (AP) -- United Therapeutics Corp. said Wednesday that its blood pressure drug treprostinil did not work better than a placebo in a late-stage clinical trial.

Analysts said the results make it less likely the Food and Drug Administration will grant marketing approval for the drug. United Therapeutics reported successful results from a separate late-stage trial in June, and the company said it still plans to file for approval in the first half of 2012.

Shares of United Therapeutics lost $8.30, or 17 percent, to $40.45 in morning trading.

The latest study was designed to evaluate oral treprostinil as a treatment for pulmonary arterial hypertension, or high blood pressure in the lungs. The patients were treated with standard therapies and either oral treprostinil or a placebo. Researchers measured how far the patients could walk in six minutes at the start of the trial, and took another measurement after 16 weeks. United Therapeutics said the patients who were given treprostinil could not walk farther than patients treated with the placebo.

The drug also did not meet secondary goals like reducing shortness of breath or fatigue, or treating other symptoms. There were 310 patients in the study. The company said that at the start of the trial, the patients' median walking distance was 333 meters, or almost 1,100 feet, in six minutes. United Therapeutics said the most common side effects of treprostinil were headache, nausea, and vomiting, and 18 treprostinil patients left the trial because of those or other side effects. Five patients from the placebo group left the trial before it finished.

In the other late-stage trial, United Therapeutics said patients treated with oral treprostinil were able to walk farther than patients who received a placebo after 12 weeks of treatment. The Silver Spring, Md., company already sells an injectable version called Remodulin and an inhaled version called Tyvaso.

Citi Investment Research analyst Lucy Lu said Wednesday's data "significantly lowers the probability of approval." Lu wrote in June that the results from the previous trial were "good, but not great." She maintained a "Buy" rating on the stock with a price target of $71 per share.

Collins Stewart analyst Salveen Richter said she was also not sure the data from the two studies would convince the FDA to approve oral treprostinil. Richter noted that the patients in the second trial were generally sicker than those in the first trial.

surf1944 surf1944 13 years ago
5:31AM United Therapeutics: FREEDOM-C trial of oral treprostinil in pulmonary arterial hypertension does not meet primary endpoint (UTHR) 48.76 : Co announces the completion of its FREEDOM-C Phase 3 trial of treprostinil diethanolamine, an investigational sustained release oral formulation of treprostinil, a stable synthetic form of prostacyclin, in patients with pulmonary arterial hypertension. Preliminary analysis demonstrates that the trial did not achieve statistical significance for the primary endpoint, six-minute walk distance at Week 16. Overall, 132 (84%) oral treprostinil and 138 (90%) placebo patients completed Week 16 with an average dose of 3.0 plus or minus 1.9 mg twice daily in the oral treprostinil group. Discontinuations due to adverse events were 18 (11%) and 5 (3%) in the treprostinil and placebo groups, respectively. Adverse events associated with discontinuations were typically prostacyclin-related effects including headache, nausea and vomiting. Preliminary analysis of other secondary efficacy measures, including time to clinical worsening, change in combined 6MWD and Borg Dyspnea Score rating and Dyspnea-Fatigue index, WHO functional class, and PAH signs and symptoms, did not differ significantly between oral treprostinil and placebo. Further review and analysis of the FREEDOM-C preliminary results are ongoing.
Kristallweizen Kristallweizen 15 years ago
United Therapeutics Reports First Quarter 2009 Financial Results

- Revenues of $79.7 Million, Increase of 29% over First Quarter 2008

SILVER SPRING, Md., May 1 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (NASDAQ:UTHR) today announced its results of operations for the quarter ended March 31, 2009. Total revenues for the first quarter of 2009 were $79.7 million, up from $62.0 million for the first quarter of 2008. Net income for the first quarter of 2009 was $13.2 million, or $0.50 per basic share, compared to $9.9 million, or $0.44 per basic share, for the first quarter of 2008. Gross margins from sales were $70.4 million for the first quarter of 2009, compared to $54.5 million for the first quarter of 2008. Earnings before non-cash charges, defined as net income before non-cash interest and income taxes, depreciation, amortization, impairment charges and share-based compensation (stock option and share tracking award expense), were $37.1 million for the first quarter of 2009, up 44% from $25.8 million for the first quarter of 2008.

Results for the first quarter of 2008 have been adjusted for the retrospective adoption of Financial Accounting Standards Board Staff Position No. APB 14-1 (FSP APB 14-1), which became effective January 1, 2009. The retrospective adoption of FSP APB 14-1 resulted in the recognition of additional non-cash interest expense of approximately $2.7 million. Also, net income was reduced by approximately $(1.5) million, representing a reduction in earnings per share of $(0.07) per basic share and $(0.06) per diluted share, from what was previously reported.

"I am pleased that we started the year with an extremely strong first quarter," said Martine Rothblatt, Ph.D., United Therapeutics' Chairman and Chief Executive Officer. "Our core Remodulin franchise continues to grow and is now the preferred form of prostacyclin in North America."

Research and Development Expenses

The table below summarizes research and development expenses by major project and non-project components (dollars in thousands):

Three Months Ended March 31, Percentage 2009 2008 Change Program: Cardiovascular $11,418 $14,485 (21.2)% Other 4,885 3,324 47.0% Share-based compensation 4,656 3,267 42.5% Total research and development expense $20,959 $21,076 (0.6)%

Cardiovascular. Cardiovascular expenses for the three months ended March 31, 2008, included a $3.0 million milestone payment made in connection with the development of a modified release version of the oral prostacyclin analogue, beraprost, under our amended agreement with Toray Industries, Inc. (Toray). There were no milestone payments made to Toray during the three months ended March 31, 2009.

Selling, General and Administrative Expenses

The table below summarizes selling, general and administrative expenses by major category (dollars in thousands):

Three Months Ended March 31, Percentage 2009 2008 Change Category: General and administrative $11,383 $8,839 28.8% Sales and marketing 8,459 6,884 22.9% Share-based compensation 9,376 3,608 159.9% Total selling, general and administrative expense $29,218 $19,331 51.2%

General and administrative. During the three months ended March 31, 2009, professional fees incurred related to follow-up services on the transactions we completed in the fourth quarter of 2008 were approximately $2.1 million higher than those for the three months ended March 31, 2008.

Share-based compensation. Share-based compensation increased for the three months ended March 31, 2009, compared to the three months ended March 31, 2008, as the result of the recognition of an estimated expense for anticipated stock option grants and the expense incurred for outstanding and unvested grants of stock options and share tracking awards.

Earnings Before Non-Cash Charges

The following table provides a reconciliation of net income to earnings before non-cash charges for the three-month periods ending March 31, 2009 and 2008 (in thousands, except per share data):

Three Months Ended March 31, 2009 2008 (as adjusted)(1)

Net income, as reported $13,197 $9,936 Add back: Amortization of debt discount 2,637 2,684 Income tax expense 5,401 5,337 Depreciation and amortization 1,765 974 Impairment charges - - Share-based compensation 14,055 6,891 Earnings before non-cash charges $37,055 $25,822 Earnings before non-cash charges per share(2): Basic $1.40 $1.16 Diluted $1.36 $1.07

(1) Adjusted for the retrospective adoption of FSP APB 14-1.

(2) Calculated by dividing earnings before non-cash charges by the weighted average number of common shares outstanding, as reported below in our Consolidated Statements of Operations.

Conference Call

United Therapeutics will host a half-hour teleconference on Friday, May 1, 2009, at 9:00 a.m. Eastern Time. The teleconference is accessible by dialing 877-718-5092, with international callers dialing 719-325-4795. A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 888-203-1112, with international callers dialing 719-457-0820, and using passcode: 9448698.

This teleconference is also being webcast and can be accessed via United Therapeutics' website at

About United Therapeutics

United Therapeutics is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer.

Non-GAAP Financial Information

This press release contains a financial measure that does not comply with U.S. generally accepted accounting principals (GAAP). This measure supplements our financial results prepared in accordance with GAAP as reported below.

We use earnings before non-cash charges, a financial non-GAAP measure, internally for operating, budgeting and financial planning purposes and as a metric to determine the efficiency of our operations and in calculating our employees' bonus compensation. We believe this measure enhances our investors' understanding of our performance. The presentation of this non-GAAP financial measure is not to be considered in isolation or as a substitute for our financial results prepared in accordance with GAAP.

Forward-looking Statements

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, our expectations and intentions related to financial performance and results, including the growth and market prominence of our Remodulin business and our belief about the future prospects for Remodulin. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and current reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of May 1, 2009, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.

Remodulin is a registered trademark of United Therapeutics Corporation. [uthr-g]


Three Months Ended March 31, 2009 2008 (as adjusted)(1) (unaudited) Revenues: Net product sales $76,858 $59,153 Service sales 2,530 2,227 License fees 342 667 Total revenues 79,730 62,047

Operating expenses: Research and development 20,959 21,076 Selling, general and administrative 29,218 19,331 Cost of product sales 8,066 6,175 Cost of service sales 920 711 Total operating expenses 59,163 47,293

Income from operations 20,567 14,754

Other income (expense): Interest income 1,721 3,716 Interest expense (2,637) (2,792) Equity loss in affiliate (19) (113) Other, net 364 (292) Total other income (expense), net (571) 519

Income before income tax 19,996 15,273

Income tax expense (6,799) (5,337)

Net income $13,197 $9,936

Net income per common share: Basic $0.50 $0.44 Diluted $0.49 $0.41

Weighted average number of common shares outstanding: Basic 26,440 22,333 Diluted 27,152 24,076

(1) Adjusted for the retrospective adoption of FSP APB 14-1.

CONSOLIDATED BALANCE SHEET DATA As of March 31, 2009 (unaudited, in thousands)

Cash, cash equivalents and marketable investments (excluding restricted amounts of $45,945) $319,365 Total assets $902,813 Total liabilities & common stock subject to repurchase $325,531 Total stockholders' equity $577,282

DATASOURCE: United Therapeutics Corporation

CONTACT: Andrew Fisher, +1-202-483-7000,

Web Site:
Kristallweizen Kristallweizen 15 years ago
Shorts covering today?

United Therapeutics Corp. $ 73.85
UTHR 7.31

Short Interest (Shares Short) 3,669,300
Days To Cover (Short Interest Ratio) 4.9
Short Percent of Float 14.36 %
Short Interest - Prior 3,565,800
Short % Increase / Decrease 2.90 %
Short Squeeze Ranking™ -19

% From 52-Wk High ($ 117.82 ) -59.54 %
% From 52-Wk Low ($ 47.63 ) 35.50 %
% From 200-Day MA ($ 64.73 ) 12.35 %
% From 50-Day MA ($ 62.65 ) 15.17 %
Price % Change (52-Week) -27.00 %

Shares Float 25,560,000
Total Shares Outstanding 26,451,577
% Owned by Insiders %
% Owned by Institutions %
Market Cap. $ 1,953,448,961
Trading Volume - Today 2,144,362
Trading Volume - Average 750,900
Trading Volume - Today vs. Average 285.57 %
Earnings Per Share -1.84
PE Ratio
Record Date 2009-MayA

Sector Healthcare
Industry Drug Manufacturers - Other
Exchange NAS
Kristallweizen Kristallweizen 15 years ago
Check out pre market action after the approval

Your Recent History

Delayed Upgrade Clock